{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:08:29Z","timestamp":1791947309298,"version":"4.3.4"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100020206","name":"Shandong Provincial Health Commission","doi-asserted-by":"publisher","award":["M20241706"],"award-info":[{"award-number":["M20241706"]}],"id":[{"id":"10.13039\/501100020206","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009108","name":"Shandong University","doi-asserted-by":"publisher","award":["KYZK2024Q26"],"award-info":[{"award-number":["KYZK2024Q26"]}],"id":[{"id":"10.13039\/100009108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82374408"],"award-info":[{"award-number":["82374408"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82405315"],"award-info":[{"award-number":["82405315"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bcp.2025.117511","type":"journal-article","created":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T22:56:37Z","timestamp":1762124197000},"page":"117511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P1","title":["Fibroblast growth factor receptor: Bidirectional regulatory role and therapeutic potential in cardiovascular disease"],"prefix":"10.1016","volume":"243","author":[{"given":"Yiming","family":"Jiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengkai","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuya","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8181-8758","authenticated-orcid":false,"given":"Lin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bcp.2025.117511_b0005","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/S2352-3018(20)30036-9","article-title":"HIV and cardiovascular disease","volume":"7","author":"So-Armah","year":"2020","journal-title":"Lancet HIV"},{"key":"#cr-split#-10.1016\/j.bcp.2025.117511_b0010.1","doi-asserted-by":"crossref","unstructured":"J. Sun, Y. Qiao, M. Zhao, C.G. Magnussen, B. Xi B. Global, regional, and national burden of cardiovascular diseases in youths and young adults aged 15-39 years in 204 countries\/territories, 1990-2019: a systematic analysis of Global Burden of Disease Study 2019, BMC Med. 21","DOI":"10.1186\/s12916-023-02925-4"},{"key":"#cr-split#-10.1016\/j.bcp.2025.117511_b0010.2","doi-asserted-by":"crossref","unstructured":"(1) (2023) 22, doi:10.1186\/s12916-023-02925-4.","DOI":"10.1186\/s12916-023-02925-4"},{"key":"10.1016\/j.bcp.2025.117511_b0015","doi-asserted-by":"crossref","unstructured":"L. Bu\u0142dak, Cardiovascular diseases-A focus on atherosclerosis, its prophylaxis, complications and recent advancements in therapies, Int. J. Mol. Sci. 23 (9) (2022), doi:10.3390\/ijms23094695.","DOI":"10.3390\/ijms23094695"},{"key":"10.1016\/j.bcp.2025.117511_b0020","doi-asserted-by":"crossref","unstructured":"M. Czyz Fibroblast growth factor receptor signaling in skin cancers, Cells 8(6) (2019), doi:10.3390\/cells8060540 2019.","DOI":"10.3390\/cells8060540"},{"issue":"3","key":"10.1016\/j.bcp.2025.117511_b0025","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.yjmcc.2007.12.008","article-title":"Fibroblast growth factor receptor 1 gene expression is required for cardiomyocyte proliferation and is repressed by Sp3","volume":"44","author":"Seyed","year":"2008","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"7","key":"10.1016\/j.bcp.2025.117511_b0030","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1161\/01.CIR.0000024113.26985.CC","article-title":"Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro","volume":"106","author":"Li","year":"2002","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.bcp.2025.117511_b0035","doi-asserted-by":"crossref","first-page":"H559","DOI":"10.1152\/ajpheart.00758.2015","article-title":"Endothelial fibroblast growth factor receptor signaling is required for vascular remodeling following cardiac ischemia-reperfusion injury","volume":"310","author":"House","year":"2016","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.bcp.2025.117511_b0040","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.matbio.2021.10.001","article-title":"Tumor vascular remodeling by thrombospondin-1 enhances drug delivery and antineoplastic activity","volume":"103\u2013104","author":"Pinessi","year":"2021","journal-title":"Matrix Biol."},{"issue":"13","key":"10.1016\/j.bcp.2025.117511_b0045","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1182\/blood-2007-01-067314","article-title":"FGFR-1 regulates angiogenesis through cytokines interleukin-4 and pleiotrophin","volume":"110","author":"Magnusson","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2025.117511_b0050","doi-asserted-by":"crossref","unstructured":"A. Wiedlocha, E.M. Haugsten, M. Zakrzewska, Roles of the FGF-FGFR signaling system in cancer development and inflammation, Cells 10 (9) (2021), doi:10.3390\/cells10092231.","DOI":"10.3390\/cells10092231"},{"issue":"2","key":"10.1016\/j.bcp.2025.117511_b0055","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2025.117511_b0060","doi-asserted-by":"crossref","unstructured":"Q. Hui, Z. Jin, X. Li, C. Liu, X. Wang, FGF Family: from drug development to clinical application, Int. J. Mol. Sci. 19 (7) (2018), doi:10.3390\/ijms19071875.","DOI":"10.3390\/ijms19071875"},{"key":"#cr-split#-10.1016\/j.bcp.2025.117511_b0065.1","doi-asserted-by":"crossref","unstructured":"Q. Liu, J. Huang, W. Yan, Z. Liu, S. Liu, W. Fang, FGFR families: biological functions and therapeutic interventions in tumors, MedComm (2020) 4","DOI":"10.1002\/mco2.367"},{"key":"#cr-split#-10.1016\/j.bcp.2025.117511_b0065.2","doi-asserted-by":"crossref","unstructured":"(5) (2023) e367, doi:10.1002\/mco2.367.","DOI":"10.1002\/mco2.367"},{"issue":"10","key":"10.1016\/j.bcp.2025.117511_b0070","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41584-020-0469-2","article-title":"Fibroblast growth factor signalling in osteoarthritis and cartilage repair","volume":"16","author":"Xie","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bcp.2025.117511_b0075","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1146\/annurev-pharmtox-032322-093904","article-title":"Fibroblast growth factor-based pharmacotherapies for the treatment of obesity-related metabolic complications","volume":"63","author":"Jin","year":"2023","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117511_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188595","article-title":"FGFR signaling and endocrine resistance in breast cancer: challenges for the clinical development of FGFR inhibitors","volume":"1876","author":"Servetto","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"11","key":"10.1016\/j.bcp.2025.117511_b0085","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.tig.2004.08.007","article-title":"Evolution of the Fgf and Fgfr gene families","volume":"20","author":"Itoh","year":"2004","journal-title":"Trends Genet."},{"issue":"1","key":"10.1016\/j.bcp.2025.117511_b0090","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.str.2011.10.022","article-title":"The alternatively spliced acid box region plays a key role in FGF receptor autoinhibition","volume":"20","author":"Kalinina","year":"2012","journal-title":"Structure"},{"key":"10.1016\/j.bcp.2025.117511_b0095","doi-asserted-by":"crossref","unstructured":"L. Chen, Y. Zhang, L. Yin, et al., Fibroblast growth factor receptor fusions in cancer: opportunities and challenges, J. Exp. Clin. Cancer Res. 40 (1) (2021) 345, doi:10.1186\/s13046-021-02156-6.","DOI":"10.1186\/s13046-021-02156-6"},{"key":"10.1016\/j.bcp.2025.117511_b0100","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.critrevonc.2017.02.018","article-title":"FGFR a promising druggable target in cancer: Molecular biology and new drugs","volume":"113","author":"Porta","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117511_b0105","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1242\/dev.125.4.753","article-title":"Fibroblast growth factor receptor 2 (FGFR2)-mediated reciprocal regulation loop between FGF8 and FGF10 is essential for limb induction","volume":"125","author":"Xu","year":"1998","journal-title":"Development"},{"key":"10.1016\/j.bcp.2025.117511_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104567","article-title":"The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder","volume":"151","author":"Roskoski","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"25","key":"10.1016\/j.bcp.2025.117511_b0115","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1021\/acs.biochem.7b00399","article-title":"Parallels and Distinctions in FGFR, VEGFR, and EGFR Mechanisms of Transmembrane Signaling","volume":"56","author":"Sarabipour","year":"2017","journal-title":"Biochemistry"},{"issue":"11","key":"10.1016\/j.bcp.2025.117511_b0120","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/j.str.2013.08.026","article-title":"Structure of FGFR3 transmembrane domain dimer: implications for signaling and human pathologies","volume":"21","author":"Bocharov","year":"2013","journal-title":"Structure"},{"issue":"8","key":"10.1016\/j.bcp.2025.117511_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0273237","article-title":"FGFRL1 and FGF genes are associated with height, hypertension, and osteoporosis","volume":"17","author":"Cho","year":"2022","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bcp.2025.117511_b0130","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00018-010-0576-3","article-title":"Biology of FGFRL1, the fifth fibroblast growth factor receptor","volume":"68","author":"Trueb","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"issue":"14","key":"10.1016\/j.bcp.2025.117511_b0135","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1007\/s00018-012-1189-9","article-title":"Role of FGFRL1 and other FGF signaling proteins in early kidney development","volume":"70","author":"Trueb","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bcp.2025.117511_b0140","article-title":"Ligand bias underlies differential signaling of multiple FGFs via FGFR1","volume":"12","author":"Karl","year":"2024","journal-title":"Elife. Apr 3"},{"key":"10.1016\/j.bcp.2025.117511_b0145","doi-asserted-by":"crossref","unstructured":"D. \u017bukowska, A. Chor\u0105\u017cewska A, Ciura K, et al. The diverse dependence of galectin-1 and -8 on multivalency for the modulation of FGFR1 endocytosis, Cell Commun. Signal. 22 (1) (2024) 270, doi:10.1186\/s12964-024-01661-3.","DOI":"10.1186\/s12964-024-01661-3"},{"issue":"2","key":"10.1016\/j.bcp.2025.117511_b0150","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s13402-022-00753-x","article-title":"Discovery of a small molecule ligand of FRS2 that inhibits invasion and tumor growth","volume":"46","author":"Santhana Kumar","year":"2023","journal-title":"Cell. Oncol. (Dordr.)"},{"key":"10.1016\/j.bcp.2025.117511_b0155","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.971162","article-title":"Negative regulation of receptor tyrosine kinases by ubiquitination: Key roles of the Cbl family of E3 ubiquitin ligases","volume":"13","author":"Tang","year":"2022","journal-title":"Front Endocrinol (lausanne)."},{"issue":"11","key":"10.1016\/j.bcp.2025.117511_b0160","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/nm.3739","article-title":"Ubiquitination in disease pathogenesis and treatment","volume":"20","author":"Popovic","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2025.117511_b0165","doi-asserted-by":"crossref","unstructured":"W. Qin, C. Steinek, K. Kolobynina, et al., Probing protein ubiquitination in live cells. Nucleic Acids Res. 50 (21) (2022) e125, doi:10.1093\/nar\/gkac805.","DOI":"10.1093\/nar\/gkac805"},{"key":"10.1016\/j.bcp.2025.117511_b0170","doi-asserted-by":"crossref","unstructured":"P. Kong, Z.Y. Cui, X.F. Huang, D.D. Zhang, R.J. Guo, M. Han Inflammation and atherosclerosis: signaling pathways and therapeutic intervention, Signal Transduct. Target Ther. 7 (1) (2022) 131, doi:10.1038\/s41392-022-00955-7.","DOI":"10.1038\/s41392-022-00955-7"},{"issue":"3","key":"10.1016\/j.bcp.2025.117511_b0175","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/pin.13202","article-title":"Atherosclerosis: known and unknown","volume":"72","author":"Fan","year":"2022","journal-title":"Pathol. Int."},{"issue":"3","key":"10.1016\/j.bcp.2025.117511_b0180","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0008-6363(96)00102-2","article-title":"Localisation and differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal and atherosclerotic human arteries","volume":"32","author":"Hughes","year":"1996","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bcp.2025.117511_b0185","doi-asserted-by":"crossref","unstructured":"S.R. Sinha, P. Prakash, J.R. Keshari, R.V. Prasad, The Correlation between serum fibroblast growth factor 21 and the severity and occurrence of coronary artery disease, Cureus 16 (1) (2024), doi: 10.7759\/cureus.51924 e51924.","DOI":"10.7759\/cureus.51924"},{"issue":"19","key":"10.1016\/j.bcp.2025.117511_b0190","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/eurheartj\/ehaf045","article-title":"Fibroblast growth factor 5: a novel biomarker for familial hypercholesterolaemia","volume":"46","author":"Baragetti","year":"2025","journal-title":"Eur. Heart J."},{"issue":"16","key":"10.1016\/j.bcp.2025.117511_b0195","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.bcp.2025.117511_b0200","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/cvr\/cvae131","article-title":"Macrophage-derived FGFR1 drives atherosclerosis through PLC\u03b3-mediated activation of NF-\u03baB inflammatory signalling pathway","volume":"120","author":"Wang","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bcp.2025.117511_b0205","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.arr.2017.05.004","article-title":"Regulation of longevity by FGF21: Interaction between energy metabolism and stress responses","volume":"37","author":"Salminen","year":"2017","journal-title":"Ageing Res. Rev."},{"issue":"12","key":"10.1016\/j.bcp.2025.117511_b0210","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1172\/JCI82719","article-title":"Endothelial-to-mesenchymal transition drives atherosclerosis progression","volume":"125","author":"Chen","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.bcp.2025.117511_b0215","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.clinthera.2023.08.015","article-title":"New targets in atherosclerosis: vascular smooth muscle cell plasticity and macrophage polarity","volume":"45","author":"Hutton","year":"2023","journal-title":"Clin. Ther."},{"issue":"4","key":"10.1016\/j.bcp.2025.117511_b0220","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/cvr\/cvy007","article-title":"Vascular smooth muscle cell death, autophagy and senescence in atherosclerosis","volume":"114","author":"Grootaert","year":"2018","journal-title":"Cardiovasc. Res."},{"issue":"9","key":"10.1016\/j.bcp.2025.117511_b0225","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/nm.3334","article-title":"Forever (FGF) 21","volume":"19","author":"Bass","year":"2013","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bcp.2025.117511_b0230","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s42255-021-00354-2","article-title":"Metabolic Messengers: FGF21","volume":"3","author":"Flippo","year":"2021","journal-title":"Nat Metab."},{"issue":"24","key":"10.1016\/j.bcp.2025.117511_b0235","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1097\/CM9.0000000000001890","article-title":"The role of FGF21 in the pathogenesis of cardiovascular disease","volume":"134","author":"Zhang","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.bcp.2025.117511_b0240","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.atherosclerosis.2019.08.017","article-title":"Inhibition of vascular neointima hyperplasia by FGF21 associated with FGFR1\/Syk\/NLRP3 inflammasome pathway in diabetic mice","volume":"289","author":"Wei","year":"2019","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.bcp.2025.117511_b0245","first-page":"162","article-title":"FGF signaling contributes to atherosclerosis by enhancing the inflammatory response in vascular smooth muscle cells","volume":"20","author":"Qi","year":"2019","journal-title":"Mol. Med. Rep."},{"issue":"7","key":"10.1016\/j.bcp.2025.117511_b0250","doi-asserted-by":"crossref","first-page":"712","DOI":"10.15252\/emmm.201506181","article-title":"Smooth muscle FGF\/TGF\u03b2 cross talk regulates atherosclerosis progression","volume":"8","author":"Chen","year":"2016","journal-title":"EMBO Mol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.117511_b0255","doi-asserted-by":"crossref","first-page":"H154","DOI":"10.1152\/ajpheart.00075.2010","article-title":"Endothelial FGF receptor signaling accelerates atherosclerosis","volume":"300","author":"Che","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"6","key":"10.1016\/j.bcp.2025.117511_b0260","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1161\/CIRCRESAHA.109.206029","article-title":"TRAIL promotes VSMC proliferation and neointima formation in a FGF-2-, Sp1 phosphorylation-, and NFkappaB-dependent manner","volume":"106","author":"Chan","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2025.117511_b0265","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","article-title":"Understanding the Physiology of FGF21","volume":"78","author":"Fisher","year":"2016","journal-title":"Annu. Rev. Physiol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117511_b0270","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/cvr\/cvab076","article-title":"Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis","volume":"118","author":"Liu","year":"2022","journal-title":"Cardiovasc. Res."},{"issue":"6","key":"10.1016\/j.bcp.2025.117511_b0275","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1093\/cvr\/cvx212","article-title":"Retracted: Transplantation of brown adipose tissue inhibits atherosclerosis in apoE-\/- mice: contribution of the activated FGF-21-adiponectin axis","volume":"114","author":"Kikai","year":"2018","journal-title":"Cardiovasc. Res."},{"issue":"21","key":"10.1016\/j.bcp.2025.117511_b0280","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1161\/CIRCULATIONAHA.115.015308","article-title":"Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice","volume":"131","author":"Lin","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2025.117511_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2024.102619","article-title":"The role of FGF15\/FGF19 in the development of the central nervous system, eyes and inner ears in vertebrates","volume":"91","author":"Hidalgo-S\u00e1nchez","year":"2024","journal-title":"Tissue Cell"},{"key":"10.1016\/j.bcp.2025.117511_b0290","doi-asserted-by":"crossref","unstructured":"T. Katafuchi, M. Makishima, Molecular basis of Bile Acid-FXR-FGF15\/19 signaling axis, Int. J. Mol. Sci. 23 (11) (2022), doi:10.3390\/ijms23116046 2022.","DOI":"10.3390\/ijms23116046"},{"issue":"2","key":"10.1016\/j.bcp.2025.117511_b0295","doi-asserted-by":"crossref","first-page":"e02210","DOI":"10.1128\/mBio.02210-15","article-title":"Resveratrol attenuates Trimethylamine-N-Oxide (TMAO)-induced atherosclerosis by regulating tmao synthesis and bile acid metabolism via remodeling of the gut microbiota","volume":"7","author":"Chen","year":"2016","journal-title":"MBio"},{"issue":"11","key":"10.1016\/j.bcp.2025.117511_b0300","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1194\/jlr.M009308","article-title":"Abolished synthesis of cholic acid reduces atherosclerotic development in apolipoprotein E knockout mice","volume":"51","author":"Sl\u00e4tis","year":"2010","journal-title":"J. Lipid Res."},{"issue":"5","key":"10.1016\/j.bcp.2025.117511_b0305","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1021\/acs.jafc.3c05709","article-title":"Bifidobacterium animalis subsp. lactis F1-7 Alleviates Lipid Accumulation in Atherosclerotic mice via Modulating Bile Acid Metabolites to Downregulate Intestinal FXR","volume":"72","author":"Liang","year":"2024","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.bcp.2025.117511_b0310","doi-asserted-by":"crossref","unstructured":"S. Zhou, S. Hua, X. Chen, et al., ZeXieYin formula alleviates atherosclerosis by regulating SBAs levels through the FXR\/FGF15 pathway and restoring intestinal barrier integrity, Chin Med. 20(1) (2025) 68, doi:10.1186\/s13020-025-01116-y.","DOI":"10.1186\/s13020-025-01116-y"},{"key":"10.1016\/j.bcp.2025.117511_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115900","article-title":"Activation of GPBAR1 attenuates vascular inflammation and atherosclerosis in a mouse model of NAFLD-related cardiovascular disease","volume":"218","author":"Biagioli","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117511_b0320","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.placenta.2021.07.286","article-title":"FGF15\/FGF19 alleviates insulin resistance and upregulates placental IRS1\/GLUT expression in pregnant mice fed a high-fat diet","volume":"112","author":"Zhao","year":"2021","journal-title":"Placenta"},{"key":"10.1016\/j.bcp.2025.117511_b0325","article-title":"Evaluation and management of hypertensive emergency","volume":"386","author":"Miller","year":"2024","journal-title":"Bmj. Jul 26"},{"issue":"4","key":"10.1016\/j.bcp.2025.117511_b0330","doi-asserted-by":"crossref","first-page":"e514","DOI":"10.1093\/oncolo\/oyad338","article-title":"First-in-human phase I study of tinengotinib (TT-00420), a multiple kinase inhibitor, as a single agent in patients with advanced solid tumors","volume":"29","author":"Piha-Paul","year":"2024","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.bcp.2025.117511_b0335","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00280-018-03765-3","article-title":"A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer","volume":"83","author":"Campone","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"11","key":"10.1016\/j.bcp.2025.117511_b0340","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1093\/annonc\/mdu390","article-title":"Phase I\/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors","volume":"25","author":"Soria","year":"2014","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2025.117511_b0345","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1093\/ajh\/hpw062","article-title":"Differential regulatory role of soluble klothos on cardiac fibrogenesis in hypertension","volume":"29","author":"Liu","year":"2016","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.bcp.2025.117511_b0350","doi-asserted-by":"crossref","unstructured":"K. Jiao, P. Su, Y. Li, FGFR2 modulates the Akt\/Nrf2\/ARE signaling pathway to improve angiotensin II-induced hypertension-related endothelial dysfunction, Clin. Exp. Hypertens. 45 (1) (2023) 2208777, doi:10.1080\/10641963.2023.2208777.","DOI":"10.1080\/10641963.2023.2208777"},{"key":"10.1016\/j.bcp.2025.117511_b0355","doi-asserted-by":"crossref","unstructured":"Z. Xiao, G. King S. Mancarella et al. FGF23 expression is stimulated in transgenic \u03b1-Klotho longevity mouse model, JCI Insight 4 (23) (2019), doi:10.1172\/jci.insight.132820.","DOI":"10.1172\/jci.insight.132820"},{"issue":"4","key":"10.1016\/j.bcp.2025.117511_b0360","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MNH.0000000000000240","article-title":"Multiple faces of fibroblast growth factor-23","volume":"25","author":"Han","year":"2016","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"1","key":"10.1016\/j.bcp.2025.117511_b0365","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1161\/HYPERTENSIONAHA.120.14703","article-title":"Fibroblast Growth factor 23 and Blood pressure in older adults: the Health, Aging, and Body Composition Study","volume":"76","author":"Drew","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2025.117511_b0370","doi-asserted-by":"crossref","unstructured":"S.M.H. Yeung, E.J. Hoorn, J.I. Rotmans, et al., Urinary potassium excretion, fibroblast growth factor 23, and incident hypertension in the general population-based PREVEND cohort. Nutrients 13 (12) (2021), doi:10.3390\/nu13124532.","DOI":"10.3390\/nu13124532"},{"key":"10.1016\/j.bcp.2025.117511_b0375","doi-asserted-by":"crossref","unstructured":"W. Xu, X. Gao, H. Luo, Y. Chen, FGF21 attenuates salt-sensitive hypertension via regulating HNF4\u03b1\/ACE2 axis in the hypothalamic paraventricular nucleus of mice, Clin Exp Hypertens. 46 (1) (2024) 2361671, doi:10.1080\/10641963.2024.2361671.","DOI":"10.1080\/10641963.2024.2361671"},{"issue":"1","key":"10.1016\/j.bcp.2025.117511_b0380","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/03014460.2023.2187457","article-title":"Genetic variants of FGFR family associated with height, hypertension, and osteoporosis","volume":"50","author":"Cho","year":"2023","journal-title":"Ann. Hum. Biol."},{"key":"10.1016\/j.bcp.2025.117511_b0385","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.brainresbull.2019.10.003","article-title":"FGF-21 ameliorates essential hypertension of SHR via baroreflex afferent function","volume":"154","author":"Chen","year":"2020","journal-title":"Brain Res. Bull."},{"issue":"7","key":"10.1016\/j.bcp.2025.117511_b0390","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1089\/gtmb.2016.0320","article-title":"Gender-specific Association between FGFR4 Gly388Arg Gene Variants and Hypertension","volume":"21","author":"Al-Daghri","year":"2017","journal-title":"Genet. Test. Mol. Biomarkers"},{"key":"10.1016\/j.bcp.2025.117511_b0395","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jot.2025.01.011","article-title":"Fibroblast growth factor receptor 3 mutation promotes HSPB6-mediated cuproptosis in hypochondroplasia by impairing chondrocyte autophagy","volume":"51","author":"Chen","year":"2025","journal-title":"J. Orthop Translat."},{"key":"10.1016\/j.bcp.2025.117511_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106840","article-title":"METTL3 boosts mitochondrial fission and induces cardiac fibrosis by enhancing LncRNA GAS5 methylation","volume":"194","author":"Tu","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2025.117511_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113982","article-title":"Elevating VAPB-PTPIP51 integration repairs damaged mitochondria-associated endoplasmic reticulum membranes and inhibits lung fibroblasts activation","volume":"147","author":"Ban","year":"2025","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.bcp.2025.117511_b0410","article-title":"FGFR inhibition blocks NF-\u0138B-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma","volume":"15(1):3805","author":"Zhen","year":"2024","journal-title":"Nat Commun. May 7"},{"issue":"5","key":"10.1016\/j.bcp.2025.117511_b0415","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1053\/j.jvca.2015.05.058","article-title":"Atrial fibrillation: pathophysiology and therapeutic options","volume":"29","author":"Bhatt","year":"2015","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"issue":"6","key":"10.1016\/j.bcp.2025.117511_b0420","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.hrthm.2021.02.019","article-title":"Who is at risk of atrial fibrillation?","volume":"18","author":"Healey","year":"2021","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.bcp.2025.117511_b0425","doi-asserted-by":"crossref","unstructured":"M. Sagris, E.P. Vardas, P. Theofilis, A.S. Antonopoulos, E. Oikonomou, D. Tousoulis, Atrial fibrillation: pathogenesis, predisposing factors, and genetics, Int. J. Mol. Sci. 23 (1) (2021), doi:10.3390\/ijms23010006.","DOI":"10.3390\/ijms23010006"},{"key":"10.1016\/j.bcp.2025.117511_b0430","doi-asserted-by":"crossref","unstructured":"A. Capucci, J.A. Reiffel, Atrial fibrillation progression: another step in the RACE to full understanding, Europace 25 (5) (2023), doi:10.1093\/europace\/euad071.","DOI":"10.1093\/europace\/euad071"},{"issue":"5","key":"10.1016\/j.bcp.2025.117511_b0435","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/ehjcvp\/pvad049","article-title":"Atrial fibrillation has gone from a boring disease to a very hot condition. why is that?","volume":"9","author":"Agewall","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"5","key":"10.1016\/j.bcp.2025.117511_b0440","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2174\/092986732605190422092911","article-title":"Biomarkers in atrial fibrillation; from pathophysiology to diagnosis and treatment","volume":"26","author":"Tousoulis","year":"2019","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2025.117511_b0445","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41569-023-00903-0","article-title":"FGF23 and klotho at the intersection of kidney and cardiovascular disease","volume":"21","author":"Edmonston","year":"2024","journal-title":"Nat. Rev. Cardiol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117511_b0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100747","article-title":"FGF-23, Left ventricular hypertrophy, andmortality in patients with CKD: a revisit with mediation analysis","volume":"3","author":"Hidaka","year":"2024","journal-title":"JACC Adv."},{"issue":"5","key":"10.1016\/j.bcp.2025.117511_b0455","article-title":"Impact of elevated fibroblast growth factor 23 (fgf23) on the cardiovascular system: a comprehensive systematic literature review","volume":"16","author":"Amaravadi","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.bcp.2025.117511_b0460","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1059179","article-title":"Direct and indirect effects of fibroblast growth factor 23 on the heart","volume":"14","author":"Nakano","year":"2023","journal-title":"Front Endocrinol. (Lausanne)."},{"issue":"16","key":"10.1016\/j.bcp.2025.117511_b0465","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/eurheartj\/ehy815","article-title":"Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation","volume":"40","author":"Chua","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2025.117511_b0470","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3162806","article-title":"Phosphate and cardiovascular disease beyond chronic kidney disease and vascular calcification","volume":"2018","author":"Disthabanchong","year":"2018","journal-title":"Int. J. Nephrol."},{"key":"10.1016\/j.bcp.2025.117511_b0475","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2147\/CIA.S450292","article-title":"Predictive value of serum microrna-29b-3p in recurrence of atrial fibrillation after radiofrequency catheter ablation","volume":"19","author":"Zhan","year":"2024","journal-title":"Clin. Interv. Aging"},{"issue":"1","key":"10.1016\/j.bcp.2025.117511_b0480","first-page":"175","article-title":"Evaluation of atrial fibrosis in atrial fibrillation patients with three different methods","volume":"52","author":"\u00c7\u00f6teli","year":"2022","journal-title":"Turk J Med Sci."},{"key":"10.1016\/j.bcp.2025.117511_b0485","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.899667","article-title":"Relationship between serum growth differentiation factor 15, fibroblast growth factor-23 and risk of atrial fibrillation: a systematic review and meta-analysis","volume":"9","author":"Tan","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"issue":"5","key":"10.1016\/j.bcp.2025.117511_b0490","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027875","article-title":"Relationship of fibroblast growth factor 23 with hospitalization for heart failure and cardiovascular outcomes in patients undergoing cardiac surgery","volume":"12","author":"Hofer","year":"2023","journal-title":"J. Am. Heart Assoc."},{"issue":"3","key":"10.1016\/j.bcp.2025.117511_b0495","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12055-021-01328-5","article-title":"Role of fibroblast growth factor-23 (FGF-23) in the prediction of postoperative atrial fibrillation after coronary artery bypass surgery","volume":"38","author":"Jadhav","year":"2022","journal-title":"Indian J. Thorac. Cardiovasc. Surg."},{"issue":"9","key":"10.1016\/j.bcp.2025.117511_b0500","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/cvr\/cvab262","article-title":"Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation","volume":"118","author":"Pol","year":"2022","journal-title":"Cardiovasc. Res."},{"issue":"12","key":"10.1016\/j.bcp.2025.117511_b0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106833","article-title":"Association of blood-based biomarkers with radiologic markers and cognitive decline in atrial fibrillation patients","volume":"31","author":"Pal\u00e0","year":"2022","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.bcp.2025.117511_b0510","article-title":"Changes in intestinal flora structure and metabolites are associated with myocardial fibrosis in patients with persistent atrial fibrillation","volume":"8","author":"Liu","year":"2021","journal-title":"Front. Nutr."},{"issue":"5","key":"10.1016\/j.bcp.2025.117511_b0515","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1002\/ehf2.12816","article-title":"Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction","volume":"7","author":"Roy","year":"2020","journal-title":"ESC Heart Fail."},{"issue":"16","key":"10.1016\/j.bcp.2025.117511_b0520","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.12998\/wjcc.v8.i16.3458","article-title":"Significance of serum fibroblast growth factor-23 and miR-208b in pathogenesis of atrial fibrillation and their relationship with prognosis","volume":"8","author":"Chen","year":"2020","journal-title":"World J. Clin. Cases"},{"key":"10.1016\/j.bcp.2025.117511_b0525","article-title":"Fibroblast growth factor 21 protects against atrial remodeling via reducing oxidative stress","volume":"8","author":"Chen","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"issue":"11","key":"10.1016\/j.bcp.2025.117511_b0530","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13488","article-title":"Suppression of the gut microbiota-bile acid-FGF19 axis in patients with atrial fibrillation","volume":"56","author":"Zuo","year":"2023","journal-title":"Cell Prolif."},{"key":"10.1016\/j.bcp.2025.117511_b0535","article-title":"Fibroblast Growth factor 1 Reduces Pulmonary Vein and Atrium Arrhythmogenesis via Modification of Oxidative stress and Sodium\/Calcium Homeostasis","volume":"8","author":"Lu","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.117511_b0540","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pcad.2019.11.009","article-title":"Left ventricular hypertrophy and hypertension","volume":"63","author":"Yildiz","year":"2020","journal-title":"Prog. Cardiovasc. Dis. Jan-Feb"},{"key":"10.1016\/j.bcp.2025.117511_b0545","doi-asserted-by":"crossref","unstructured":"C. Cunha, Electrocardiographic Diagnosis of Left Ventricular Hypertrophy, Arq Bras Cardiol. 117 (5) (2025) 932-933. Diagn\u00f3stico Eletrocardiogr\u00e1fico da Hipertrofia Ventricular Esquerda, doi:10.36660\/abc.20210868.","DOI":"10.36660\/abc.20210868"},{"issue":"2","key":"10.1016\/j.bcp.2025.117511_b0550","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40119-022-00260-y","article-title":"Left ventricular hypertrophy: etiology-based therapeutic options","volume":"11","author":"Sayin","year":"2022","journal-title":"Cardiol Ther."},{"issue":"2","key":"10.1016\/j.bcp.2025.117511_b0555","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41440-022-01119-4","article-title":"Left ventricular hypertrophy was not built in a day","volume":"46","author":"Kida","year":"2023","journal-title":"Hypertens. Res."},{"issue":"2","key":"10.1016\/j.bcp.2025.117511_b0560","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ccep.2015.03.017","article-title":"Left ventricular hypertrophy and arrhythmogenesis","volume":"7","author":"Shenasa","year":"2015","journal-title":"Card Electrophysiol Clin."},{"issue":"7000","key":"10.1016\/j.bcp.2025.117511_b0565","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/bmj.311.7000.273","article-title":"Left ventricular hypertrophy","volume":"311","author":"Chambers","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.bcp.2025.117511_b0570","unstructured":"A. Bondue, [Left ventricular hypertrophy: how to identity the cause ?], Rev. Med. Brux. 39 (4) (2018) 227-236, Mise au point d\u2019une hypertrophie ventriculaire gauche : comment en identifier la cause?."},{"key":"10.1016\/j.bcp.2025.117511_b0575","doi-asserted-by":"crossref","unstructured":"M.A. Fuchs, E.J. Burke, N. Latic, et al. Fibroblast Growth Factor (FGF) 23 and FGF Receptor 4 promote cardiac metabolic remodeling in chronic kidney disease, Res. Sq., 2023 doi:10.21203\/rs.3.rs-3705543\/v1.","DOI":"10.21203\/rs.3.rs-3705543\/v1"},{"key":"10.1016\/j.bcp.2025.117511_b0580","doi-asserted-by":"crossref","unstructured":"Taylor A, Yanucil C, Musgrove J, et al. FGFR4 does not contribute to progression of chronic kidney disease. Sci Rep. Oct 1 2019;9(1):14023. doi:10.1038\/s41598-019-50669-0.","DOI":"10.1038\/s41598-019-50669-0"},{"key":"10.1016\/j.bcp.2025.117511_b0585","doi-asserted-by":"crossref","unstructured":"C. Rodelo-Haad, R. Santamaria, J.R. Mu\u00f1oz-Casta\u00f1eda, M.V. Pend\u00f3n-Ruiz de Mier, A. Martin-Malo, M. Rodriguez, FGF23, Biomarker or Target? Toxins (Basel), 11 (3) (2019), doi:10.3390\/toxins11030175.","DOI":"10.3390\/toxins11030175"},{"key":"10.1016\/j.bcp.2025.117511_b0590","doi-asserted-by":"crossref","unstructured":"A. Grabner, K. Schramm, N. Silswal et al., FGF23\/FGFR4-mediated left ventricular hypertrophy is reversible. Sci Rep. 7 (1) (2017) 1993, doi:10.1038\/s41598-017-02068-6.","DOI":"10.1038\/s41598-017-02068-6"},{"issue":"7","key":"10.1016\/j.bcp.2025.117511_b0595","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/ndt\/gfv421","article-title":"Induction of cardiac FGF23\/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease","volume":"31","author":"Leifheit-Nestler","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"issue":"6","key":"10.1016\/j.bcp.2025.117511_b0600","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.cmet.2015.09.002","article-title":"Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy","volume":"22","author":"Grabner","year":"2015","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.bcp.2025.117511_b0605","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/ajh\/hpt177","article-title":"Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats","volume":"27","author":"Freundlich","year":"2014","journal-title":"Am. J. Hypertens."},{"issue":"11","key":"10.1016\/j.bcp.2025.117511_b0610","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1093\/ndt\/gfu190","article-title":"Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD","volume":"29","author":"Di Marco","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"issue":"5","key":"10.1016\/j.bcp.2025.117511_b0615","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.kint.2025.01.024","article-title":"Fibroblast growth factor 23 and fibroblast growth factor receptor 4 promote cardiac metabolic remodeling in chronic kidney disease","volume":"107","author":"Fuchs","year":"2025","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.bcp.2025.117511_b0620","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.kint.2025.02.017","article-title":"Fibroblast growth factor (FGF) 23 and FGF receptor 4 induced cardiac mitochondrial dysfunction as a new target in CKD?","volume":"107","author":"Haffner","year":"2025","journal-title":"Kidney Int."},{"key":"10.1016\/j.bcp.2025.117511_b0625","doi-asserted-by":"crossref","unstructured":"J.R. Baman, F.S. Ahmad, Heart Failure, Jama. 324 (10) (2020) 1015, doi:10.1001\/jama.2020.13310.","DOI":"10.1001\/jama.2020.13310"},{"issue":"2","key":"10.1016\/j.bcp.2025.117511_b0630","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10741-021-10105-w","article-title":"Biomarkers for the diagnosis and management of heart failure","volume":"27","author":"Castiglione","year":"2022","journal-title":"Heart Fail. Rev."},{"issue":"7","key":"10.1016\/j.bcp.2025.117511_b0635","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jchf.2024.03.020","article-title":"Practical guidance for hemodynamic assessment by right heart catheterization in management of heartfailure","volume":"12","author":"Rajagopalan","year":"2024","journal-title":"JACC Heart Fail."},{"issue":"6","key":"10.1016\/j.bcp.2025.117511_b0640","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jacc.2020.05.075","article-title":"Heartfailure with recovered leftventricular ejection fraction: JACC scientific expert panel","volume":"76","author":"Wilcox","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bcp.2025.117511_b0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116329","article-title":"FGF13 deficiency ameliorates calcium signaling abnormality in heart failure by regulating microtubule stability","volume":"225","author":"Zhao","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2025.117511_b0650","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2215\/CJN.00960122","article-title":"Association of genetically predicted fibroblast growth factor-23 with heart failure: a mendelian randomization study","volume":"17","author":"Akwo","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"11","key":"10.1016\/j.bcp.2025.117511_b0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100723","article-title":"Fibroblast growth factor 23 and risk of heart failure subtype: the CRIC (Chronic Renal Insufficiency Cohort) study","volume":"5","author":"Leidner","year":"2023","journal-title":"Kidney Med."},{"key":"10.1016\/j.bcp.2025.117511_b0660","doi-asserted-by":"crossref","unstructured":"Z.L. Yu, Z.H. Cai, J.T. Zheng et al., Serum fibroblast growth factor-2 levels complement vital biomarkers for diagnosing heart failure, BMC Cardiovasc Disord. 24 (1) (2024)109, doi:10.1186\/s12872-024-03768-4.","DOI":"10.1186\/s12872-024-03768-4"},{"key":"10.1016\/j.bcp.2025.117511_b0665","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12943-015-0391-4","article-title":"Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy","volume":"14","author":"Ling","year":"2015","journal-title":"Mol Cancer. 23"},{"issue":"2","key":"10.1016\/j.bcp.2025.117511_b0670","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase I dose-expansion study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.bcp.2025.117511_b0675","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1254\/fpj.24045","article-title":"Pharmacological characteristics and clinical effectiveness of Futibatinib (Lytgobi(\u00ae) Tablets), a covalently-binding, irreversible FGFR1-4 inhibitor","volume":"159","author":"Takagaki","year":"2024","journal-title":"Nihon Yakurigaku Zasshi."},{"issue":"9","key":"10.1016\/j.bcp.2025.117511_b0680","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/2159-8290.CD-23-0475","article-title":"RLY-4008, the first Highly Selective FGFR2 Inhibitor with activity across FGFR2 alterations and resistance mutations","volume":"13","author":"Subbiah","year":"2023","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.bcp.2025.117511_b0685","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","article-title":"FGF21 agonists: an emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond","volume":"81","author":"Harrison","year":"2024","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117511_b0690","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.annonc.2024.12.011","article-title":"A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma","volume":"36","author":"Goyal","year":"2025","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117511_b0695","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.eururo.2024.11.001","article-title":"Expanding the reach of FGFR inhibitors to advance precision medicine in urothelial carcinoma","volume":"87","author":"Koshkin","year":"2025","journal-title":"Eur. Urol."},{"issue":"21","key":"10.1016\/j.bcp.2025.117511_b0700","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1158\/1078-0432.CCR-24-1834","article-title":"Understanding and overcoming resistance to selective FGFR inhibitors across FGFR2-driven malignancies","volume":"30","author":"Facchinetti","year":"2024","journal-title":"Clin. Cancer Res."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225007762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225007762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T05:01:51Z","timestamp":1775797311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225007762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":142,"alternative-id":["S0006295225007762"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117511","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fibroblast growth factor receptor: Bidirectional regulatory role and therapeutic potential in cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117511","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117511"}}